Dogwood Therapeutics, Inc.
DWTXHealthcareNASDAQBiotechnology · Last scanned Oct 22, 2026
Scan Results
Daily timeframeDogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. At a $39.8M market cap, Dogwood Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Market Cap
$39.8M
Beta
1.94
P/E (TTM)
0.53
P/E (Fwd)
-0.18
EPS (TTM)
$2.20
EPS (Fwd)
$-6.37
ROE
-47.8%
ROA
-20.8%
Cash
$9.6M
Total Debt
$127,208
Free CF
-$16.4M
52W Change
-79.2%
Annual Financials
Cash vs Debt
Where DWTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DWTX finished 31.25% below its 150-day moving average ($1.76) and 41.83% below its 200-day moving average ($2.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DWTX overbought or oversold?
At the October 20, 2026 close, DWTX's RSI(14) was 35.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.6M in cash comfortably exceeding the $127K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$16.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -47.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Dogwood Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, DWTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DWTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.